Masimo (MASI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$179.950.00%
Close 2026-06-10 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Research Workspace
Put MASI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar broken — Operating margin near 30% in 2025-FY: 20.3% vs 30% target.
View ThesisManagement screens strong on earnings delivery, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 56% growth a year, above the roughly 0% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 0% a day.
View RiskMasimo's growth depends on successfully completing the acquisition of Danaher. Revenue growth has been strong, supported by FDA pediatric clearance. The stock trades at a typical multiple compared to peers, but the market cycle is currently in a "Mania" phase. The primary risk is the operating margin, which is near 20.3% versus a 30% target. Peer multiples imply a price about 12% above where it trades. This read is provisional.
Trailing returns as of 2026-06-10. MASI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering MASI (as of Jun 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare MASI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MASI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put MASI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete acquisition of Danaher
FDA clearance supports growth through acquisition of Danaher.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-06-10. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Advances: Complete acquisition of Danaher
Danaher's growth forecast supports Masimo's acquisition strategy.
Threatens: Complete acquisition of Danaher
Danaher's mixed results may impact acquisition confidence.
Advances: Increase revenue growth
FDA approval enhances revenue growth potential significantly.
Advances: Increase revenue growth
New offering aligns with revenue growth objective.
Activist investor action may disrupt management focus.